Charles Schwab
CAMP icon

Charles Schwab’s CAMP4 Therapeutics CAMP Stock Holding History

Charles Schwab’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422K Buy
96,660
+76,660
+383% +$331K ﹤0.01% 3267
2026
Q1 		$88.2K Buy
+20,000
New +$94.9K ﹤0.01% 3398
2025
Q2 		– Sell
-16,685
Closed -$66.7K – 3503
2025
Q1 		$66.7K Hold
16,685
– – ﹤0.01% 3378
2024
Q4 		$87.1K Buy
+16,685
New +$137K ﹤0.01% 3406

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's CAMP Position: Q2 2026 in Review

Charles Schwab increased its CAMP4 Therapeutics (CAMP) stake by 383% in Q2 2026, buying an estimated $331K and bringing the position to 96,660 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #3267.

Charles Schwab first reported a position in CAMP in Q4 2024 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Charles Schwab held 96,660 shares of CAMP4 Therapeutics worth $422K as of Q2 2026.
  • Charles Schwab bought 76,660 CAMP4 Therapeutics shares in Q2 2026, an estimated $331K.
  • CAMP4 Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3267 holding.
  • Charles Schwab first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.